BRY Fundamental Analysis - BRI-CHEM CORP

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to BRY. BRY was compared to 12 industry peers in the Trading Companies & Distributors industry. BRY may be in some trouble as it scores bad on both profitability and health. BRY does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year BRY has reported negative net income.

BRY had a positive operating cash flow in the past year.

The reported net income has been mixed in the past 5 years: BRY reported negative net income in multiple years.

The reported operating cash flow has been mixed in the past 5 years: BRY reported negative operating cash flow in multiple years.

1.2 Ratios

BRY has a Return On Assets of -3.45%. This is amonst the worse of the industry: BRY underperforms 91.67% of its industry peers.

The Return On Equity of BRY (-8.61%) is worse than 91.67% of its industry peers.

		Industry Rank	Sector Rank
ROA	-3.45%
ROE	-8.61%
ROIC	N/A

ROA(3y)1.89%

ROA(5y)-2.15%

ROE(3y)7.6%

ROE(5y)-2.84%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

BRY has a worse Gross Margin (17.27%) than 66.67% of its industry peers.

In the last couple of years the Gross Margin of BRY has remained more or less at the same level.

The Profit Margin and Operating Margin are not available for BRY so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	17.27%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-4.96%

GM growth 5Y-0.62%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BRY does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, BRY has about the same amount of shares outstanding.

Compared to 5 years ago, BRY has more shares outstanding

BRY has a better debt/assets ratio than last year.

2.2 Solvency

BRY has an Altman-Z score of 1.54. This is a bad value and indicates that BRY is not financially healthy and even has some risk of bankruptcy.

BRY's Altman-Z score of 1.54 is on the low side compared to the rest of the industry. BRY is outperformed by 91.67% of its industry peers.

BRY has a debt to FCF ratio of 4.10. This is a neutral value as BRY would need 4.10 years to pay back of all of its debts.

BRY has a Debt to FCF ratio (4.10) which is in line with its industry peers.

BRY has a Debt/Equity ratio of 0.93. This is a neutral value indicating BRY is somewhat dependend on debt financing.

With a Debt to Equity ratio value of 0.93, BRY is not doing good in the industry: 83.33% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	0.93
Debt/FCF	4.1
Altman-Z	1.54

ROIC/WACCN/A

WACC8.6%

2.3 Liquidity

BRY has a Current Ratio of 1.48. This is a normal value and indicates that BRY is financially healthy and should not expect problems in meeting its short term obligations.

The Current ratio of BRY (1.48) is worse than 75.00% of its industry peers.

A Quick Ratio of 0.60 indicates that BRY may have some problems paying its short term obligations.

BRY has a Quick ratio of 0.60. This is amonst the worse of the industry: BRY underperforms 91.67% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.48
Quick Ratio	0.6

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.78% over the past year.

The Revenue for BRY has decreased by -11.17% in the past year. This is quite bad

BRY shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.96% yearly.

EPS 1Y (TTM)7.78%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%158.82%

Revenue 1Y (TTM)-11.17%

Revenue growth 3Y11.21%

Revenue growth 5Y-1.96%

Sales Q2Q%-17.22%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

BRY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, BRY is valued a bit more expensive than 75.00% of the companies in the same industry.

BRY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BRY is cheaper than 100.00% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	1.44
EV/EBITDA	13.71

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for BRY!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BRI-CHEM CORP

TSX:BRY (12/5/2025, 7:00:00 PM)

0.25

+0.02 (+8.7%)

Chartmill FA Rating

GICS SectorIndustrials

GICS IndustryGroupCapital Goods

GICS IndustryTrading Companies & Distributors

Earnings (Last)11-17 2025-11-17

Earnings (Next)03-30 2026-03-30

Inst OwnersN/A

Inst Owner ChangeN/A

Ins Owners7.8%

Ins Owner ChangeN/A

Market Cap6.61M

Revenue(TTM)79.26M

Net Income(TTM)-1.68M

Analysts0

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.08
P/FCF	1.44
P/OCF	1.31
P/B	0.34
P/tB	0.34
EV/EBITDA	13.71

EPS(TTM)-0.06

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)0.17

FCFY69.48%

OCF(TTM)0.19

OCFY76.34%

SpS3

BVpS0.74

TBVpS0.74

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-3.45%
ROE	-8.61%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	17.27%
FCFM	5.79%

ROA(3y)1.89%

ROA(5y)-2.15%

ROE(3y)7.6%

ROE(5y)-2.84%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-4.96%

GM growth 5Y-0.62%

F-Score4

Asset Turnover1.62

Health

		Industry Rank	Sector Rank
Debt/Equity	0.93
Debt/FCF	4.1
Debt/EBITDA	18.07
Cap/Depr	37.43%
Cap/Sales	0.57%
Interest Coverage	N/A
Cash Conversion	499.39%
Profit Quality	N/A
Current Ratio	1.48
Quick Ratio	0.6
Altman-Z	1.54

F-Score4

WACC8.6%

ROIC/WACCN/A

Cap/Depr(3y)93.13%

Cap/Depr(5y)56.73%

Cap/Sales(3y)1.06%

Cap/Sales(5y)0.65%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)7.78%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%158.82%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-11.17%

Revenue growth 3Y11.21%

Revenue growth 5Y-1.96%

Sales Q2Q%-17.22%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-111.52%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y466.79%

FCF growth 3YN/A

FCF growth 5Y-15.31%

OCF growth 1Y58.13%

OCF growth 3YN/A

OCF growth 5Y-14.89%

BRI-CHEM CORP / BRY.CA FAQ

Can you provide the ChartMill fundamental rating for BRI-CHEM CORP?

ChartMill assigns a fundamental rating of 1 / 10 to BRY.CA.

What is the valuation status of BRI-CHEM CORP (BRY.CA) stock?

ChartMill assigns a valuation rating of 2 / 10 to BRI-CHEM CORP (BRY.CA). This can be considered as Overvalued.

What is the profitability of BRY stock?

BRI-CHEM CORP (BRY.CA) has a profitability rating of 1 / 10.

BRI-CHEM CORP (BRY.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

BRI-CHEM CORP / BRY.CA FAQ

Can you provide the ChartMill fundamental rating for BRI-CHEM CORP?

What is the valuation status of BRI-CHEM CORP (BRY.CA) stock?

What is the profitability of BRY stock?